(0.35%) 5 117.78 points
(0.34%) 38 368 points
(0.40%) 15 992 points
(-0.98%) $83.03
(5.51%) $2.03
(0.34%) $2 355.20
(0.46%) $27.66
(4.08%) $959.75
(-0.25%) $0.932
(-0.41%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer...
Stats | |
---|---|
本日の出来高 | 5 022.00 |
平均出来高 | 21 096.00 |
時価総額 | 20.39M |
EPS | $0 ( 2024-02-08 ) |
次の収益日 | ( $-1.520 ) 2024-05-09 |
Last Dividend | $1.750 ( 2023-11-16 ) |
Next Dividend | $0 ( N/A ) |
P/E | 1.030 |
ATR14 | $0.0260 (0.86%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-18 | Flynn James P | Buy | 10 000 | Stock Option (Right to Buy) |
2023-12-18 | Flynn James P | Buy | 6 700 | Stock Option (Right to Buy) |
2023-12-18 | Wood Steven D | Buy | 10 000 | Stock Option (Right to Buy) |
2023-12-18 | Wood Steven D | Buy | 6 700 | Stock Option (Right to Buy) |
2023-12-18 | Wood Steven D | Buy | 10 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
93.08 |
Last 96 transactions |
Buy: 9 932 993 | Sell: 849 643 |
MEI Pharma Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
MEI Pharma Inc 財務諸表
Annual | 2023 |
収益: | $48.82M |
総利益: | $47.00M (96.28 %) |
EPS: | $-4.78 |
FY | 2023 |
収益: | $48.82M |
総利益: | $47.00M (96.28 %) |
EPS: | $-4.78 |
FY | 2022 |
収益: | $40.70M |
総利益: | $39.46M (96.97 %) |
EPS: | $-8.80 |
FY | 2021 |
収益: | $25.54M |
総利益: | $24.13M (94.49 %) |
EPS: | $-0.450 |
Financial Reports:
No articles found.
MEI Pharma Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$1.750 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $1.750 | 2023-11-16 |
Last Dividend | $1.750 | 2023-11-16 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-06 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $1.750 | -- |
Avg. Dividend % Per Year | 11.67% | -- |
Score | 4.75 | -- |
Div. Sustainability Score | 5.51 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 2.48 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $1.750 | 35.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.286 | 1.500 | 4.27 | 6.41 | [0 - 0.5] |
returnOnAssetsTTM | 0.265 | 1.200 | 1.173 | 1.408 | [0 - 0.3] |
returnOnEquityTTM | 0.416 | 1.500 | 6.49 | 9.73 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 8.23 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.40 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.644 | 1.500 | 7.54 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.153 | -1.500 | 7.45 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -16.44 | 1.000 | -7.20 | -7.20 | [3 - 30] |
operatingCashFlowPerShareTTM | -7.95 | 2.00 | -2.65 | -5.30 | [0 - 30] |
freeCashFlowPerShareTTM | -7.95 | 2.00 | -3.97 | -7.95 | [0 - 20] |
debtEquityRatioTTM | 0.202 | -1.500 | 9.19 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.980 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.219 | 1.000 | 7.63 | 7.63 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -4.40 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.925 | 0.800 | 7.17 | 5.73 | [0.5 - 2] |
Total Score | 5.51 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0.977 | 1.000 | -0.00231 | 0 | [1 - 100] |
returnOnEquityTTM | 0.416 | 2.50 | 7.74 | 9.73 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -7.95 | 2.00 | -2.65 | -7.95 | [0 - 30] |
dividendYielPercentageTTM | 114.75 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -7.95 | 2.00 | -2.65 | -5.30 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.729 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -0.560 |
MEI Pharma Inc
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。